Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Production. Per the activity note to the FY2024 annual report, the company manufactures pharmaceutical products. The company operates in its own factory.
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 333 | 2,435 | 1,978 | 2,861 | 1,997 | 1,891 | 5,010 | +57.1% |
| Total COGS | 66 | 609 | 458 | 708 | 709 | 946 | 1,842 | +74.2% |
| Gross Profit | 268 | 1,826 | 1,520 | 2,153 | 1,288 | 945 | 3,169 | +51.0% |
| Gross Margin | 80.3% | 75.0% | 76.8% | 75.3% | 64.5% | 50.0% | 63.2% | |
| 39 | 459 | 545 | 722 | 453 | 395 | 336 | +43.3% | |
| EBITDA | 229 | 1,367 | 976 | 1,431 | 835 | 549 | 2,832 | +52.1% |
| EBITDA Margin | 68.6% | 56.1% | 49.3% | 50.0% | 41.8% | 29.1% | 56.5% | |
| Total D&A | 3 | 29 | 29 | 29 | 29 | 24 | 5 | +7.4% |
| EBIT / Operating Income | 226 | 1,338 | 947 | 1,401 | 806 | 525 | 2,828 | +52.4% |
| Total Interest Income | 0 | 0 | 0 | 0 | 0 | 13 | 0 | |
| Total Interest Expense | 0 | 348 | 286 | 198 | 83 | 54 | 39 | -35.6% |
| 13 | 64 | 71 | 104 | 321 | 106 | 42 | +22.3% | |
| Profit Before Tax | 213 | 926 | 731 | 1,099 | 402 | 378 | 2,747 | +53.1% |
| Total Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 216 | 926 | 731 | 1,099 | 402 | 378 | 2,747 | +52.8% |
| Net Margin | 64.8% | 38.0% | 37.0% | 38.4% | 20.1% | 20.0% | 54.8% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →